精选 · 数据与分析B2B 分析中的整合：如何优化业务数据
您的销售数据在 Salesforce 中，营销活动在 Google Ads 中，账目在 Stripe 中，但谁也无法与谁沟通。整合改变了一切：无需编写代码即可连接 7000 多个应用程序，线索自动同步，执行报告自动编译。Zapier 将以前需要专门技术团队才能完成的工作平民化。作为 Zapier 解决方案合作伙伴，我们帮助中小企业建立数据管道，将碎片化转化为竞争优势。
Fabio Lauria我们发布的一切内容，都在这里。
文章都在这里；播客、Newsletter 和季刊各有自己的主页——均可从此中心访问。
全部文章
全部文章精选 · 数据与分析Fabio Lauria播客
AI Frontiers
aifrontiers.electe.net深入探讨应用型 AI 的发展方向。每周更新。
The ELECTE Review
thereview.electe.net5 分钟回顾本周 AI 与商业新闻。每日更新。
最新思考
来自 ELECTE 幕后团队的笔记——未经编辑，保留原始语言。
Fabio LauriaEveryone treats SME AI adoption as a cost problem. The data says otherwise, and the mismatch is expensive. Entry cost for small firms fell roughly 60% — from ~$50/month for 2019 adopters to ~$20/month for 2024 adopters (JPMorgan Chase Institute, 2025). Over the same window, the EU gap between large enterprises (55%) and small firms (17%) widened to 38 percentage points (Eurostat, 2025). Prices collapsed. The divide grew. That should end the affordability narrative. The sharper signal: small employer firms adopted at 27.6%, while larger non-employer firms sat at 19%. Having people beat having revenue. Familiarity tracks headcount too — 48% among sole proprietors versus 82% at firms with 50+ employees (NFIB, 2025). What most vendors and most subsidy schemes miss is what happens after purchase. A Danish administrative-record study found no significant effect on earnings or hours two years after adoption, despite real reported time savings. Meanwhile 83% of SME generative-AI users report no change in staffing needs while 65% report better employee performance (OECD, 5,000+ firms). Value comes from redesigning work, not from buying tools or cutting heads. That is a management task. It requires someone with authority, allocated hours, and a defined process to rebuild. Only 17% of leaders rate their organisation as highly capable of executing transformational change. So: in your last AI initiative, who owned the process redesign — and how many of their hours were formally protected for it? And where, specifically, did the saved time go?AI entry cost for small firms fell ~60% since 2019 — roughly $50/month for 2019 adopters to $20/month for 2024 adopters (JPMorgan Chase Institute).
Over the same stretch, the EU adoption gap widened to 38 points: 55% of large enterprises, 17% of small firms.
Price was never binding.
— Fabio Lauria (@fabiolauria92) Sep 1, 2026Everyone wants the AI, nobody wants the janitorial work that makes it function. I've watched more projects die from broken pipelines than bad algorithms, and the boring infrastructure is the actual moat.
@electesrlRevenue-cycle analytics: 40.5% of 2025 healthcare analytics spend. Payers and life-science: 45% of end users. The 'clinical insight' market is largely billing optimisation in a lab coat.Blunt version: healthcare BI is mostly a compliance tax with a dashboard. If the lowest-cost providers get penalised for not affording the software that proves they're low-cost, the metric isn't measuring value. It's measuring who could afford the licence.Acquiring a new customer can cost up to 25x more than keeping one you have. This week's ELECTE Digest: fixing follow-up mistakes, behavioral segmentation, customer lifetime value, and an energy audit deadline you shouldn't miss. x.com/i/article/209294208422…
— @ElecteSrl Aug 31, 2026Everyone reads healthcare analytics as a productivity market. Look at where the money actually goes and it reads as something else entirely. Financial and revenue-cycle analytics captured 40.54% of the 2025 healthcare analytics market, and payers plus life-science accounted for 44.65% of end users (Mordor Intelligence, 2025). Epic's Cogito suite alone sits in 18% of US hospitals. This is not a clinical-insight market. It is a scoring and billing-optimisation market with a clinical narrative attached. The consequence is uncomfortable. Robust EHR/analytics implementation costs $32,000-$70,000 per full-time physician. A system spreads that across hundreds of doctors; a solo practice cannot. In 2024, over 45% of solo-practice clinicians were penalised under MIPS versus 31% of larger groups — while independent practices show lower per-patient spending and fewer preventable admissions. The cheapest, highest-quality providers are being penalised for not affording the tooling that proves they are cheap and high-quality. Europe should recognise the pattern. MDR already showed how compliance cost concentrates supply among large players. EHDS reporting obligations will do the same to clinical data unless reporting is treated as shared infrastructure rather than a per-practice capex line. The practical move I keep recommending: separate compliance reporting from analytics. Rent the first as a metric-scoped service. Buy the second only when it changes a decision. Who in your market is paying platform prices for what is functionally a regulatory receipt? And should reporting infrastructure be pooled at association level rather than bought practice by practice?Everyone wants to scale before they've built anything worth multiplying. Scale is not a growth strategy, it's a leverage machine, and it amplifies whatever you feed it, including the mess.
@electesrlHealthcare BI's growth curve doesn't track better outcomes. It tracks fewer independent practices. US physicians hospital-employed: under 30% in 2012, 47% in 2024 — precisely the years analytics adoption scaled. The market expanded as its smallest customers vanished.
— Fabio Lauria (@fabiolauria92) Aug 31, 2026Everyone obsesses over data collection. Cookie banners, consent forms, opt-ins. Theatre, mostly. The real value transfer happens one layer up: at inference. What a system concludes about you from data you willingly handed over. Your purchase history is worth little. The prediction that you're about to churn, get pregnant, or default — that's the asset. Europe's institutions have figured this out. Three CJEU rulings and a €200M DMA fine all point at the same thing: not what gets collected, but what gets derived. Consent frameworks built for collection don't govern conclusions. At Electe we build analytics for SMEs, so I sit on both sides of this. My view: companies that treat inference as the regulated surface — not just raw data — will be ahead of the curve instead of scrambling behind it. The collection debate is over. The inference debate is just starting.The Omnibus deferred precisely the obligations SMEs never trigger. Only 2% of small firms have any AI governance framework - not because compliance crushed them, but because nothing is deployed yet.The whole idea of licensing a font is about to collapse under its own weight. When every brand can grow a living typeface tuned to its exact voice, you stop buying letters and start buying models, and the foundries who see that first inherit the next decade.
@electesrl
Anne AndersonStoring data in Europe ≠ controlling it. Find out in the video the difference between residency and sovereignty.AI adoption doesn’t have to be all or nothing. Find out in the video the step-by-step approach for SMEs.We put together a practical guide covering the key imputation methods, when to use each one, and how they impact your analytics outcomes. Read the full breakdown here: electe.net/post/missing-data…
— @ElecteSrl Aug 31, 2026Do SMEs need data scientists to adopt AI? Not necessarily. Find out in the video how to start small and smart.
更多 ELECTE 内容
每周分析，超过 10 万订阅者。
为欧洲商业领袖提供的 AI、预测与战略内容。提供英语和意大利语版本。
newsletter.electe.net一份关于 AI 与判断力的印刷复刻期刊。
当期内容、往期存档及订阅信息均在其独立网站上。
quarterly.electe.netELECTE 周边商品
六款产品，采用统一的风格设计。在独立网站上销售。
merch.electe.net五分钟看懂本周要点。
中小企业经营者的实用要闻，即学即用。英文，发布于 LinkedIn。
linkedin.comELECTE 社交媒体
幕后团队